These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1856140)

  • 1. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation.
    Viscoli C; Dudley M; Ferrea G; Boni L; Castagnola E; Barretta MA; Lanino E; Loy A; Moroni C; Somenzi M
    J Antimicrob Chemother; 1991 May; 27 Suppl C():113-20. PubMed ID: 1856140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Ann Intern Med; 1993 Oct; 119(7 Pt 1):584-93. PubMed ID: 8363169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens.
    Marik PE; Havlik I; Monteagudo FS; Lipman J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():81-9. PubMed ID: 1856148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single daily dose amikacin in paediatric patients with severe gram-negative infections.
    Trujillo H; Robledo J; Robledo C; Espinal D; Garces G; Mejia J; Restrepo C; Restrepo F; Mejia de Rodriguez GI; Tamayo de Guitierrez MC
    J Antimicrob Chemother; 1991 May; 27 Suppl C():141-7. PubMed ID: 1856143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections.
    Kafetzis DA; Sianidou L; Vlachos E; Davros J; Baïramis T; Papandreou Y; Paraskaki E; Scouroliakou M; Hadzis A; Papadatos J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():105-12. PubMed ID: 1906861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group.
    Maller R; Ahrne H; Holmen C; Lausen I; Nilsson LE; Smedjegård J
    J Antimicrob Chemother; 1993 Jun; 31(6):939-48. PubMed ID: 8360131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study.
    Meunier F; Van der Auwera P; Aoun M; Ibrahim S; Tulkens PM
    J Antimicrob Chemother; 1991 May; 27 Suppl C():129-39. PubMed ID: 1856142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.
    ; Calandra T; Klastersky J; Gaya H; Glauser MP; Meunier F; Zinner SH
    N Engl J Med; 1987 Dec; 317(27):1692-8. PubMed ID: 2892130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 'high-dose' amikacin in children.
    Kumor KM; McDonald JM; Lietman PS
    Dev Pharmacol Ther; 1984; 7(6):368-76. PubMed ID: 6518944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections.
    Giamarellou H; Yiallouros K; Petrikkos G; Moschovakis E; Vavouraki E; Voutsinas D; Sfikakis P
    J Antimicrob Chemother; 1991 May; 27 Suppl C():73-9. PubMed ID: 1906864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.
    Finley RS; Fortner CL; deJongh CA; Wade JC; Newman KA; Caplan E; Britten J; Wiernik PH; Schimpff SC
    Antimicrob Agents Chemother; 1982 Aug; 22(2):193-7. PubMed ID: 6765414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. Scandinavian Amikacin Once Daily Study Group.
    Maller R; Ahrne H; Eilard T; Eriksson I; Lausen I
    J Antimicrob Chemother; 1991 May; 27 Suppl C():121-8. PubMed ID: 1856141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.
    Beaucaire G; Leroy O; Beuscart C; Karp P; Chidiac C; Caillaux M
    J Antimicrob Chemother; 1991 May; 27 Suppl C():91-103. PubMed ID: 1856149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical, pharmacokinetic and therapeutic study of amikacin with single daily dose and in combination in neutropenic children with fever].
    Bertrand Y; Bréant V; Vray C; Nakache C; Barbé G; Dürr F; Aulagner G
    Arch Pediatr; 1996 Sep; 3(9):854-60. PubMed ID: 8949344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia.
    Schmid L; Jeschko M; Wilder-Smith C; Schafroth U; Thürlimann B; Pedrazzini A; Senn H
    Chemotherapy; 1991; 37(5):346-52. PubMed ID: 1804595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.